InnoCare Reports First Patient Dosing with ICP-189 in the P-Ib Trial for Treating Non-Small Cell Lung Cancer
Shots:
- InnoCare has dosed the first patient in the P-Ib clinical evaluation of ICP-189 + fumetinib for treating advanced or metastatic non-small cell lung cancer (NSCLC) across China
- The company collaborated with ArriVent BioPharma in Jul 2023 to expedite the development of ICP-189 in combination with fumetinib (EGFR kinase inhibitor) for treating advanced or metastatic NSCLC
- ICP-189 (oral) is a SHP2 allosteric inhibitor demonstrating effectiveness when used as a monotx. and favorable PK characteristics as well as safety were observed in its dose-escalation trial with 120 mg without any DLTs
Ref: InnoCare | Image: Innocare
Related News:- InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
